[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561122":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":52,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Iowa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PET Imaging of breast cancer patients","EXPERIMENTAL","Triple negative breast cancer patients will undergo FDG PET\u002FCT and Pyl PET\u002FCt",[13],"Diagnostic Test: PET imaging",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","PET imaging","Imaging with FDG PET\u002FCT and Pyl PET\u002FCT in triple negative breast cancer",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ahmad Shariftabrizi, M.D.","CONTACT","319-887-4942","ashariftabrizi@uiowa.edu",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Elina Shrestha","319 335 0114","eshrestha@uiowa.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"University of Iowa Healthcare","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-91.53017,41.66113,{"lat":44,"lon":43},[47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Ahmad Shariftabrizi","Clinical Assistant Professor",[53],{"name":54,"class":55},"Progenics Pharmaceuticals, Inc.","INDUSTRY","100561122","early-phase-1-breast-cancer-psma-pet-100561122",false,"NCT06586047","Breast Cancer PSMA PET","Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET\u002FCT","Inclusion Criteria:\n\n* Female \\>= 18 years of age\n* Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.\n* Patient should have FDG positive metastatic lesions on the initial PET\u002FCT scan performed in this study to be further included.\n\nExclusion Criteria:\n\n* Patients with known active other malignancy.\n* Unable to tolerate PET\u002FCT procedure.\n* Pregnant or breastfeeding.\n* Patients with any medical condition that might compromise the safety of subject during PET acquisitions.","FEMALE","18 Years","90 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"EARLY_PHASE1","The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET\u002FCT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.",[74],"Triple Negative Breast Cancer",[76],"Breast cancer, PSMA expression, PET imaging","2026-08-05",{"date":79,"type":80},"2026-08-06","ACTUAL",{"date":82,"type":80},"2024-08-29",{"date":84,"type":68},"2027-09-01",{"name":50,"class":6},1]